Financial Performance - The company's revenue for Q1 2023 was ¥121,392,447.24, representing a 16.37% increase compared to ¥104,314,490.66 in the same period last year[7] - Net profit attributable to shareholders was ¥15,275,796.35, a 47.03% increase from ¥10,389,651.14 year-on-year[7] - The basic earnings per share increased to ¥0.20, up 11.11% from ¥0.18 in the previous year[7] - The total profit for the period was ¥17,237,207.56, a 47.31% increase compared to ¥11,701,557.15 in the previous year[11] - Net profit for Q1 2023 reached CNY 15,275,796.35, representing a 46.5% increase from CNY 10,389,651.14 in Q1 2022[23] - The company reported a total comprehensive income of CNY 15,358,257.21 for Q1 2023, compared to CNY 10,440,458.21 in the previous year[24] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,304,372,027.11, a slight increase of 0.24% from ¥1,301,260,787.30 at the end of the previous year[7] - Total current assets amount to ¥937,645,629.92, slightly up from ¥936,534,975.25 at the beginning of the year[19] - Total liabilities as of Q1 2023 were CNY 173,306,295.87, down from CNY 188,376,403.68 in the previous year[23] - Total current liabilities decreased to ¥91,455,047.87 from ¥100,874,095.92, a reduction of about 9.4%[19] - Non-current liabilities include lease liabilities of ¥78,264,069.34, down from ¥80,426,253.75[19] Cash Flow - The net cash flow from operating activities decreased by 50.88% to ¥13,556,647.25, down from ¥27,600,828.05 in the same period last year[12] - Cash flow from operating activities for Q1 2023 was CNY 13,556,647.25, a decrease of 50.9% from CNY 27,600,828.05 in Q1 2022[25] - The cash flow from investment activities showed a significant outflow of ¥425,843,102.78, indicating substantial investment in construction projects[12] - The net cash flow from investment activities was -425,843,102.78 CNY, indicating a significant outflow compared to the previous period[26] - Total cash inflow from financing activities was 2,243,221.74 CNY, while cash outflow was 4,653,403.39 CNY, resulting in a net cash flow of -4,653,403.39 CNY[26] - The net increase in cash and cash equivalents for the quarter was -418,568,830.61 CNY, a notable decrease from the previous quarter[26] - The ending balance of cash and cash equivalents was 335,073,505.57 CNY, down from 753,642,336.18 CNY at the beginning of the period[26] - Cash outflow for the acquisition of fixed assets and intangible assets totaled 70,662,185.02 CNY[26] - The company reported a total cash outflow from investment activities of 580,262,185.02 CNY[26] Shareholder Information - Total number of common shareholders at the end of the reporting period is 8,013[14] - The largest shareholder, Hongbo Zhiyuan (Hong Kong) Medical Technology Co., Ltd., holds 27.64% of shares, totaling 21,250,000 shares[14] - The top ten shareholders collectively hold significant stakes, with the top three accounting for over 39.49% of total shares[14] Expenses - Sales expenses increased by 68.35% to ¥2,563,164.87, reflecting increased investment in market development[11] - Total operating costs for Q1 2023 were CNY 104,504,260.72, up 13.1% from CNY 92,457,818.09 in the same period last year[22] - Research and development expenses increased to CNY 10,163,571.92 in Q1 2023, up 27.5% from CNY 7,974,960.23 in Q1 2022[22] Other Information - The company received government subsidies amounting to ¥413,168.87, related to its normal business operations[9] - The company recorded a significant increase in fair value gains of CNY 901,397.80 in Q1 2023, compared to a loss of CNY 395,647.75 in Q1 2022[23] - The company did not conduct an audit for the first quarter report[27] - The company experienced a foreign exchange loss of -1,628,971.69 CNY affecting cash and cash equivalents[26]
泓博医药(301230) - 2023 Q1 - 季度财报